Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijlh.14284 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obinutuzumab interference with immunoelectrophoresis in a case of follicular lymphoma.
Int J Lab Hematol
October 2024
Department of Hematology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts.
Cancers (Basel)
March 2024
Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany.
B cell acute lymphoblastic leukemia (B-ALL) is characterized by an accumulation of malignant precursor cells. Treatment consists of multiagent chemotherapy followed by allogeneic stem cell transplantation in high-risk patients. In addition, patients bearing the BCR-ABL1 fusion gene receive concomitant tyrosine kinase inhibitor (TKI) therapy.
View Article and Find Full Text PDFStromal cell inhibition of anti-CD20 antibody mediated killing of B-cell malignancies.
Front Cell Dev Biol
October 2023
Targeted Therapy Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
The glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab has been licensed for treatment in follicular non-Hodgkin lymphoma and B-CLL following clinical trials demonstrating superior outcomes to standard of care treatment. However, ultimately many patients still relapse, highlighting the need to understand the mechanisms behind treatment failure to improve patient care. Resistance to chemotherapy is often caused by the ability of malignant B-cells to migrate to the bone marrow and home into the stromal layer.
View Article and Find Full Text PDFTherapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies.
Neurotherapeutics
April 2022
Department of Medicine, Hematology Unit, University of Padova, Padova, Italy.
Article Synopsis
- Autoimmune diseases of the peripheral nervous system have primarily been treated with high-dose intravenous immunoglobulins (IVIg), which help by neutralizing harmful autoantibodies and modulating immune responses.
- Due to a shortage of IVIg, new treatments are emerging, including B cell depleting monoclonal antibodies like rituximab, particularly for conditions unresponsive to IVIg such as anti-MAG antibody neuropathy and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Other promising therapies include eculizumab, targeting complement activation, and FcRn blockers like efgartigimod, which is currently being investigated for CIDP after success in treating myasthenia gravis
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
Am J Hematol
December 2021
Department I of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Center of Excellence on "Cellular Stress Responses in Aging-Associated Diseases", University of Cologne, Köln, Germany.
Disease Overview: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and of apoptosis in clonal B-cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!